Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states
申请人:——
公开号:US20030040625A1
公开(公告)日:2003-02-27
This invention provides a class of therapeutic compounds and methods for the treatment of mammals with physiological disorders, such as for example a frequently occurring type of essential hypertension, which are critically associated with the decreased binding of magnesium to the plasma membranes of their cells. These methods consist of administering to a mammal in need of such treatment a compound selected from a series of disubstituted trans, trans 1,3-butadienes, 1,3-disubstituted perhydrobutadienes, 1,2-disubstituted trans ethylenes and 1,2 disubstituted ethanes and disubstitutedpropanes, each of which embodies, in common, the unique structural feature essential for the biological activity of these compounds. This invention also provides for pharmaceutical formulations that employ these novel compounds.
本发明提供了一类治疗化合物和方法,用于治疗患有生理紊乱的哺乳动物,例如经常出现的一种先天性高血压,这种生理紊乱与镁与细胞质膜结合力下降密切相关。这些方法包括向需要这种治疗的哺乳动物施用选自一系列二取代反式、反式 1,3-丁二烯、1,3-二取代全氢丁二烯、1,2-二取代反式乙烯和 1,2-二取代乙烷和二取代丙烷的化合物,其中每种化合物都共同体现了这些化合物的生物活性所必需的独特结构特征。本发明还提供了采用这些新型化合物的药物制剂。